16th Dec 2020 22:00
Sareum Holdings PLC - Cambridge-based specialist drug development company focused on cancer and autoimmune diseases - Says Tuesday its key focus remains on advancing development of two TYK2/JAK1 programmes, namely SDC-1801, targeting autoimmune diseases, and SDC-1802, targeting cancer. Says it has made further good progress with its proprietary TYK2/JAK1 programmes.
"The past year has been a challenging period for many people and companies. We are, however, pleased to report that Sareum has adapted well to the new working conditions and constraints imposed by the Covid-19 pandemic. The company has made good further progress and has seized an opportunity to obtain government funding to investigate one of its drug candidates as a potential treatment for Covid-19," says Chair Stephen Parker.
Current stock price: 1.6 pence
Year-to-date change: up sharply from 0.36p
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum